Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
Roth Capital Downgrades Peregrine Pharmaceuticals (PPHM) to Neutral
February 26, 2016 7:21 AM ESTRoth Capital downgraded Peregrine Pharmaceuticals (NASDAQ: PPHM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Shares of Peregrine Pharmaceuticals closed at $1.07 yesterday.
... More